Convert slides into a BioPharma commercial strategy audit.
This first module extracts the commercial thesis, audience strategy, marketing/sales assumptions, DTC/DTP opportunities, evidence gaps, and launch-stage risk so the CEO can turn a deck into a governed planning workflow.
Clear need for one aligned commercial narrative that connects marketing strategy, sales execution, DTC education, and DTP activation without turning one deck into every workflow.
ClarifyEvidence should be separated into approved facts, assumptions, commercial hypotheses, and claims requiring medical/legal/regulatory/MLR review.
Review neededSeparate CEO, marketing, sales/field, HCP, patient/caregiver, payer/access, medical, legal, and MLR needs. Do not use one master deck for every audience.
High leverageDefine what belongs in pre-launch planning vs legally approved commercial launch execution across marketing, sales, DTC, and DTP.
GuardrailFind the Commercial Strategy Plan hiding inside the deck.
The engine turns fragmented slides into a single BioPharma commercial thesis: market problem, stakeholder need, DTC/DTP role, sales motion, differentiated POV, what must be true, and CEO decision required.
Align every stakeholder without forcing one message on everyone.
Pro Evolve should help the BioPharma CEO generate audience-specific versions of the strategy without creating disconnected sales, marketing silos, lost memory, or unapproved claims.
Needs commercial choices, tradeoffs, resource implications, decision rights, and accountable owners.
Needs evidence boundaries, substantiation, and safer alternatives.
Needs approved talk tracks, objection handling, CRM follow-up workflow, and feedback loops to marketing/medical.
Needs evidence expectations, access narrative, economic logic, and coverage pathway where appropriate.
Separate strategic language from approved claims.
The dashboard should never imply AI approves claims. It flags claims, evidence gaps, risk level, and required human review.
Can be used if source and context are documented.
Low riskUseful for strategy but not for external claim use without review.
InternalRequires medical/legal/regulatory/compliance review before use.
High careGenerate conservative alternatives for human reviewers to consider.
Draft onlyTurn the plan into an operating system, not another deck.
This is the Pro Evolve “aha”: the deck becomes a repeatable commercial operating workflow with source materials, owners, approval gates, outputs, prompts, DTC/DTP paths, sales feedback, and a weekly learning loop.
REWRITE the current state into ExO 3.0.
The dashboard guides BioPharma CEOs through a pragmatic REWRITE sequence that moves the current commercial strategy toward ExO 3.0 without pretending the whole organization changes overnight.
Audit deck, current strategy, marketing/sales alignment, DTC/DTP gaps, plan drift, claims risk, and stakeholder gaps.
Define ExO 3.0 destination, Intelligence Stack, prompt workflow, source materials, decision rights, and plan template.
Run the strategy plan through one use case or stakeholder path.
Measure clarity, cycle time, review issues, and adoption before expansion.
Your BioPharma Commercial Strategy Plan.
This is the CEO-ready output clients should be able to print as a PDF after completing the end-to-end workflow.
PDF plan
Use browser print to save this final plan as PDF.
Next build
Ingest the BioPharma strategy deck and turn extracted findings into reusable saved modules.
Discuss buildout